(Q33876297)

English

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

3

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Alessandra Ferrajoli

6

object named as

Alessandra Ferrajoli

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

4

object named as

Stefan Faderl

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

5

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Gautam Borthakur

1

object named as

Gautam Borthakur

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Jean-Pierre J Issa

10

object named as

Jean-Pierre Issa

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

2

object named as

Xuelin Huang

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

8

object named as

Gail Morris

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

9

object named as

Donald Berry

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Ritva Torma

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

publication date

1 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

51

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

73-78

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

DNA methylation as a therapeutic target in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Strategies for reversing drug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Altered 5-azacytidine metabolism following 3-deazauridine treatment of L5178Y and human myeloblasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Cellular differentiation, cytidine analogs and DNA methylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Cytidine deaminase and the development of resistance to arabinosyl cytosine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Biological effects of 5-azacytidine in eukaryotes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Azapyrimidine nucleosides: metabolism and inhibitory mechanisms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Metabolism and cytotoxicity of 5-azacytidine in cultured Novikoff rat hepatoma and P388 mouse leukemia cells and their enhancement by preincubation with pyrazofurin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Combination chemotherapy of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

In vitro biochemical and cytotoxicity studies with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine in combination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

Effects of 5-azacytidine on nucleolar RNA and the preribosomal particles in Novikoff hepatoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

5 July 2018

DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428190903318329

21 January 2018

Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428190903318329

21 January 2018

A parallel phase I/II clinical trial design for combination therapies.

1 reference

https://api.crossref.org/works/10.3109%2F10428190903318329

21 January 2018

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.3109%2F10428190903318329

21 January 2018

Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876330

29 October 2018

Incorporation of 5-azacytidine into liver ribonucleic acids of leukemic mice sensitive and resistant to 5-azacytidine

1 reference

https://pubmed.ncbi.nlm.nih.gov/20017599

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kinetic studies on phosphorylation of 5-azacytidine with the purified uridine-cytidine kinase from calf thymus

1 reference

https://pubmed.ncbi.nlm.nih.gov/20017599

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reactivation of an inactive human X chromosome: evidence for X inactivation by DNA methylation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20017599

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine

1 reference

https://pubmed.ncbi.nlm.nih.gov/20017599

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20017599

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein

1 reference

https://pubmed.ncbi.nlm.nih.gov/20017599

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of cytarabine and decitabine in combination in human leukemic cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/20017599

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3109/10428190903318329

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33876297&oldid=1951428588"